Technology Results for "Therapeutics"

Available Technologies

06HSC039 Inhibition of the epidermal growth factor receptor exerts a cytoprotective effect in the gastric mucosa

07HSC010 Use of statins that are currently FDA approved for cholesterol reduction inhibit hepatitis C and hepatitis B viral replication in vivo and improve sustained viral remission when combined with interferon and will improve liver disease when used ...

07HSC017 Use of Self Compacted DNA Nanoparticles for Ocular Diseases

04HSC020 Stabilization of Cardiac Rhythm and Function with a Heart Implanted Sensor-Stimulator

04HSC008 Method and apparatus for electrically stimulating the nervous system to reduce cross sensitization of visceral organs during visceral diseases

03HSC018 Discovery of a Novel Enzyme that Enhances the Proficiency of a2-antiplasmin as an Inhibitior of Blood Clot Removal

02HSC035 Stimulation of the neural heirachy to induce neurohumoral treatment for heart failure

06HSC028 Interferon Gamma Inhibition of Herpes Virus Infection

06HSC006 A Serine Kinase Inhibitor as a Novel Anthrax Therapeutic

05HSC037 Inhibition of Angiogenesis and Expression of Genes Involved in Blood Vessels

05HSC038 Regulation of the Hepatocyte Nuclear Factor-4 (HNF-4) Receptor

05HSC039 Induction of Apoptosis Through Regulation of Gene Expression

05HSC040 Prevention of Cancer by Reversing Abnormal Differentiation and Inducing Apoptosis

05HSC043 Novel Heteroarotinoids as Potential Inhibitors of Human PKD

05HSC047 Nanoceria Particles Provide Neuronal Protection in Retinal Cells

05HSC049 Vaccine against West-Nile Virus

06HSC018 Antiarrhythmic actions of cisatracurium

04HSC050 Endoscopic Cardiac Ablation Catheters

04HSC058 Sindbis Virus and Related Plus-Stranded RNA Viruses as Oncolytic Reagents for Cancer Therapy

05HSC003 Activation of cardiac alpha receptors by spinal cord stimulation produces cardioprotection against ischemia, arrhythmias, and heart failure

04HSC061 Use of conjugated Polyunsaturated Fatty Acids as Anti-Cancer and Anti-Angiogenic Agents

07NOR004 New Cancer Treatment Aimed at Destruction of Cancer Tumors

Licensed Technologies

07HSC015 Vaccine to help prevent periodontal disease in dogs

07HSC026 Use of a novel curcumin analog to treat colon cancer

03HSC053 A New Function of Angiostatin

05HSC052 Treatment of Ocular Infections and Wounds by CAP37

04HSC063 Potential Therapeutic Effect of Angiostatin on Diabetic Nephropathy

98HSC021 Lysine Decarboxylase Inhibitors for Prevention and Treatment of Periodontal Disease

94HSC023 Method and Composition for the Treatment of Septic Shock

01HSC015 Alleviation of Chronic Pain with Glutamate Inhibition

01HSC039 Relief of Chronic Pain via Peripheral Neurotransmitter Regulation

04HSC045 Catheter and method, in particular for ablation and like technique

05HSC012 Development and Use of a Chimeric Protein for Therapy of Bleeding Disorders and Cancer

05HSC021 Plasminogen Kringle 5 Reduces Vascular Leakage and Protects Blood-Retinal Barrier

06NOR034 New Cancer Treatment Aimed at the Detection and Destruction of Cancer Tumors

07NOR001 New Cancer Treatment Aimed at Destruction of Cancer Tumors [With Nomadics Info]

02HSC008 Glycosulfopeptides as inhibitors of inflammation in vivo

03HSC010 Relief of Pain via Peripheral Neurotransmitter Regulation

04HSC016 Antioxidant Agents Used in combination with or Chemically Linked to Mesalamine for The Treatment of Inflammatory Bowel Disease